Keyword: Congress

Complacent about drug-pricing action in Congress? Despite the chaos of impeachment and elections, lawmakers are still taking drug pricing seriously.

The jury's out on how Washington will move on drug pricing this year, but one analyst believes 2020 will bring "minimal action."

With U.S. elections looming and drug pricing a hot-button issue for voters, will lawmakers take action, or will gridlock continue in 2020?

Drug pricing remains a prominent topic heading into 2020, and developments last week show pharma will likely be on the defensive during the election.

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

This week could bring a drug pricing showdown in the House as Dems plan to vote on Pelosi’s bill and Republicans aim to unveil their own bill.

FDA nominee Stephen Hahn faced questions from senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

Nearly 8 in 10 Americans believe drug costs are too high, according to a new poll, and as the elections near, voters will be watching.

Merck CEO Ken Frazier knows the industry is in the political "crosshairs," but he cautioned against policies that could "hurt innovation."

Nancy Pelosi unveiled her much anticipated drug pricing plan, but Mitch McConnell said the Senate wouldn't take up the legislation.